Journals / Türk Biyokimya Dergisi / 2020 / Cilt: 45 - Sayı: 5

Evaluation of E2F3 and survivin expression in peripheral blood as potential diagnostic markers of prostate cancer

Pages
525–532
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further, survivin expression level wasassociated with increased the risk of PC.Conclusion: Survivin and E2F3 relative expression levels inperipheral blood had low diagnostic performance to detectPC and individuals with high survivin expression levelsmay have higher risk to develop PC.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Prostate cancer (PC) incidence has risenglobally.
📊
Key Findings & Data:As there are no current independent biomarkerswith high diagnostic efficiency to detect PC, this studywas performed to investigate the relative gene expressionlevels of E2F3 and survivin in the whole blood of PC,benign prostate hyperplasia (BPH), and normal controlindividuals and to explore their diagnostic value.Material and methods: Participants of the study weredivided into three groups; normal control group (n=25),BPH patients (n=25), and PC patients (n=75).
💡
Conclusion & Impact:Further, survivin expression level wasassociated with increased the risk of PC.Conclusion: Survivin and E2F3 relative expression levels inperipheral blood had low diagnostic performance to detectPC and individuals with high survivin expression levelsmay have higher risk to develop PC.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: Prostate cancer (PC) incidence has risenglobally. As there are no current independent biomarkerswith high diagnostic efficiency to detect PC, this studywas performed to investigate the relative gene expressionlevels of E2F3 and survivin in the whole blood of PC,benign prostate hyperplasia (BPH), and normal controlindividuals and to explore their diagnostic value.Material and methods: Participants of the study weredivided into three groups; normal control group (n=25),BPH patients (n=25), and PC patients (n=75). The E2F3 andsurvivin gene expression levels were assessed using realtime qPCR in addition to the measurement of free and totallevels of prostate-specific antigen (PSA) using electrochemiluminescence assays.Results: Survivin relative gene expression was overexpressed in PC and BPH patients compared to thenormal control group, whereas, E2F3 did not differ significantly among the studied groups. Compared to PSA, E2F3and survivin mRNA expression levels had lower diagnosticefficacy to differentiate PC from normal and BPH individuals with an area under curve (AUC) of 0.471 and0.727, respectively. Further, survivin expression level wasassociated with increased the risk of PC.Conclusion: Survivin and E2F3 relative expression levels inperipheral blood had low diagnostic performance to detectPC and individuals with high survivin expression levelsmay have higher risk to develop PC.

Özet

Amaç: Prostat kanseri insidansı global olarak artmaktadır. Prostat kanserini saptayacak yüksek tanısal etkinlikte güncel bağımsız biyobelirteçler olmaması nedeniyle, bu çalışma E2F3 ve survivin genlerinin göreceli ekspresyon düzeylerinin tam kanda benign prostat hiperplazisi (BPH), prostat kanseri (PC) ve normal kontrollerde incelenmesi amacıyla yapılmıştır. Gereç ve Yöntem: Katılımcılar normal kontrol (n=25), BPH hastaları (n=25) ve PC hastalrı olarak üç gruba ayrılmıştır. E2F3 ve surviving gen ekspresyonları gerçek zamanlı qPCR yöntemiyle, serbest ve total prostat spesifik antijen (PSA) düzeyleri ise elektrokemilüminesans yöntemi ile ölçülmüştür. Bulgular: Survivin geminin ekspresyonu PC ve BPH has talarında normal kontrollere göre artmış bulunup, E2F3 gen ekspresyonunda çalışma grupları arasında anlamlı fark bulunamamıştır PSA ile kıyaslandığında, E2F3 ve surviving mRNA ekspresyon düzeylerinin PC hastalarını normal kontrol ve BPH hastalarından ayırıcılığının düşük tanısal etkinliği olduğu sırasıyla AUC değerlerinin 0,727 ve 0,471 bulunması ile gösterilmiştir. Ayrıca, survivin ekspresyon düzeyinin prostat kanseri riskini arttırdığı gösterilmiştir. Sonuç: Survivin ve E2F3 genlerinin periferik kandaki göreceli ekspresyon düzeyleri prostat kanserinin saptan masında düşük tanısal performanslıdır ve yüksek survivin ekspresyon düzeyleri olan bireylerde prostat kanseri gel işme riski daha yüksektir.

🔖

Cite This Article

SOLIMAN, A. F., HAMID, F. F. A., ALLAH, A. M. W., IBRAHIM, N., ABDELGAWAD, I. A., MALASH, I. (2022). Evaluation of E2F3 and survivin expression in peripheral blood as potential diagnostic markers of prostate cancer. Türk Biyokimya Dergisi, Cilt: 45 - Sayı: 5, 525–532. https://ajindex.com/articles/620783

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, et al. Global Burden of Disease Cancer Collaboration, Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: A systematic analysis for the global burden of disease study, JAMA Oncol 4 (2018) 1553–1568
  2. Pernar CH, Ebot EM, Wilson KM, Mucci LA, The epidemiology of prostate cancer, Cold Spring Harb Perspect Med 8 (2018) a030361
  3. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019;144:1941–53
  4. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424
  5. Brawer MK. Prostate-specific antigen. Semin Surg Oncol 2000; 18:3–9
  6. Bai VU, Kaseb A, Tejwani S, Divine GW, Barrack ER, Menon M, et al. Identification of prostate cancer mRNA markers by averaged differential expression and their detection in biopsies, blood, and urine. Proc Natl Acad Sci 2007;104:2343–8
  7. Alzghoul S, Hailat M, Zivanovic S, Que L, Shah GV. Measurement of serum prostate cancer markers using a nanopore thin film based optofluidic chip. Biosens Bioelectron 2016;77:491–8
  8. Gómez-Gómez E, Jiménez-Vacas JM, Pedraza-Arévalo S, LópezLópez F, Herrero-Aguayo V, Hormaechea-Agulla D, et al., Oncogenic role of secreted engrailed homeobox 2 (EN2) in prostate cancer, J Clin Med 8 (2019) 1400
  9. Jiménez-Vacas JM, Gómez-Gómez E, Montero-Hidalgo AJ, HerreroAguayo V, L-López F, Sánchez-Sánchez R. Clinical utility of ghrelin-O-acyltransferase (GOAT) enzyme as a diagnostic tool and potential therapeutic target in prostate cancer. J Clin med 2019;8:pii E2056.
  10. Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, Jannink SA, et al. Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score. Eur Urol 2016;70: 740–8
  11. Eder IE, Bektic J, Haag P, Bartsch G, Klocker H. Genes differentially expressed in prostate cancer. BJU Int 2004;93:1151–5
  12. Pipinikas CP, Nair SB, Kirby RS, Carter ND, Fenske CD. Measurement of blood E2F3 mRNA in prostate cancer by quantitative RT-PCR: a preliminary study. Biomarkers 2007;12: 541–57
  13. Gao Y, Feng